Lenalidomidă Grindeks

Lenalidomide, the active ingredient in Lenalidomidă Grindeks, is an immunomodulatory imide drug presented as a tablet for oral use. It is employed in the treatment of certain blood cancers, including multiple myeloma, mantle‑cell lymphoma, and myelodysplastic syndromes with del(5q). GNH USA supplies Lenalidomidă Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to EU quality standards and provides reliable logistics for global distribution.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Mantle cell lymphoma: contributes to disease control in patients who have received prior therapies. - Myelodysplastic syndromes (with del(5q)): induces transfusion independence and cytogenetic remission in affected individuals.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Anemia - Diarrhea - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or thrombocytopenia - Secondary primary malignancies - Hepatic toxicity - Severe skin reactions such as Stevens‑Johnson syndrome - Deep vein thrombosis or pulmonary embolism

Before initiating therapy, clinicians should assess baseline laboratory values and risk factors. - Monitor blood counts: perform regular CBC with differential. - Assess thromboembolic risk: consider prophylactic anticoagulation when indicated. - Contraindicated in pregnancy: ensure effective contraception for women of child‑bearing potential. - Adjust dose in renal impairment according to renal function. - Store below 25°C: keep in the original pack, protect from moisture and light.

Lenalidomide may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase exposure. - Strong CYP3A4 inducers (e.g., rifampin): may reduce effectiveness. - Anticoagulants (e.g., warfarin): heightened risk of bleeding.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., midazolam): possible altered plasma levels. - NSAIDs (e.g., ibuprofen): may increase bleeding tendency. - Hormonal contraceptives: reduced contraceptive efficacy, consider alternative methods.